Novartis Net Invested Capital from 2010 to 2024

NVS Stock  USD 96.73  0.85  0.89%   
Novartis Net Invested Capital yearly trend continues to be comparatively stable with very little volatility. Net Invested Capital is likely to outpace its year average in 2024. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
71.2 B
Current Value
73.4 B
Quarterly Volatility
11.9 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many exotic indicators such as Short Term Coverage Ratios of 1.51, Price Earnings Ratio of 13.62 or Price To Sales Ratio of 3.66. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
This module can also supplement Novartis' financial leverage analysis and stock options assessment as well as various Novartis Technical models . Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Novartis AG ADR over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Novartis' Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

Novartis Net Invested Capital Regression Statistics

Arithmetic Mean95,557,093,333
Geometric Mean94,794,830,954
Coefficient Of Variation12.48
Mean Deviation9,688,142,222
Median102,593,000,000
Standard Deviation11,926,573,615
Sample Variance142243158.2T
Range39.5B
R-Value(0.76)
Mean Square Error65745967.2T
R-Squared0.57
Significance0
Slope(2,014,861,429)
Total Sum of Squares1991404214.6T

Novartis Net Invested Capital History

202473.4 B
202371.2 B
202285.5 B
202196.8 B
202092.4 B
201982.7 B
2018110.7 B

About Novartis Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's Net Invested Capital, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Net Invested Capital71.2 B73.4 B

Novartis Investors Sentiment

The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novartis' public news can be used to forecast risks associated with an investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis AG ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novartis.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out the analysis of Novartis Correlation against competitors.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.